MUMBAI (Reuters) - Shares in Ranbaxy Laboratories Ltd , India's No.1 drugmaker by sales, turned positive after earlier falling as much as 7.4 percent after the Supreme Court of India dismissed a public interest lawsuit against the company.
The court said the petitioner had failed to provide material in support of his petition, said Manohar Lal Sharma, the lawyer who had filed the lawsuit alleging the company had manufactured substandard quality medicine. (Reporting by Suchitra Mohanty and Abhishek Vishnoi; editing by Tony Munroe)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app